Skip to main content
Premium Trial:

Request an Annual Quote

NIMH Awards $161K to Cofactor Genomics to Develop Circular RNA Enrichment Kit

NEW YORK (GenomeWeb) – Genomics services provider Cofactor Genomics has won $161,000 from the National Institute of Mental Health to develop a circular RNA enrichment kit.

The St. Louis-based company will use the Phase I Small Business Innovation Research grant to develop a standardized enrichment kit and define the reference profile for circular RNAs in the nervous system.

Circular RNA is noncoding, present in the cytoplasm, plays a role in neuronal development, and can serve as a biomarker for psychiatric disorders, according to Cofactor. In addition, circRNAs are present in lower abundance than other RNA molecules, and share sequence homology with mRNA, so they are difficult to isolate from total RNA.

"This is an opportunity to bring Cofactor's expertise in kit and software development together with our team's focus on RNA characterization solutions to develop a unique product that addresses a very specific need," Cofactor CEO Jarret Glasscock said in a statement.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.